Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: *

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Payment Terms: L/C

    Abemaciclib is an oral cyclin-dependent kinase CDK4/6 inhibitor. In HR +, HER2-breast cancer cells, CDK4 and CDK6 promote phosphorylation of retinoblastoma protein (retinoblastomapChemicalbookrotein, Rb) and promote cell cycle progression and cell proliferation. Abemaciclib inhibits phosphorylation of Rb and blocks cell progression from the G1 phase of the cell cycle to the S phase, resulting in cell aging and apoptosis

Send your message to this supplier
  • From:
  • To:
    Quanzhou Fortune Biopharma Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service